Hospital-wide antifungal prescription in Greek hospitals: a multicenter repeated point-prevalence study
The aim of the study was to evaluate antifungal prescriptions among hospitalized adult patients in Greek hospitals. This multicenter two-times, 1-day, point-prevalence study was carried out in 2015 and 2017 in five and six hospitals, respectively. Among the 5812 patients screened in both periods, antifungals were prescribed in 129 patients (73 in 2015 and 56 in 2017); antifungals were used as prophylaxis in 31 patients (24%), pre-emptively in 32 (25%), empirically in 38 (30%), and as targeted therapy in 28 (22%). Triazoles were the class most commonly used (65 patients; 50%), followed by echinocandins (59; 46%) and liposomal amphotericin B (12; 9%). The use of echinocandins was higher (P 0.009) in the ICU (16 out of 22 patients), as compared with those in other departments (40%). Antifungal treatment was deemed inappropriate in 32/129 patients (25%) (16% in 2015 versus 36% in 2017; P 0.014). Inappropriate antifungal administration was more common if indicated by the primary physician, as compared with an infectious disease specialist (35% versus 5%; P < 0.001). Candidemia represented the majority of microbiologically documented infections (12 out of 28). Only two cases of proven pulmonary aspergillosis were diagnosed. Fluconazole and echinocandins were most frequently prescribed for identified or presumptive fungal infections, while fluconazole or posaconazole was given most frequently as prophylaxis. Antifungal treatment has been, ultimately, proven unnecessary in one-fourth of cases, underlining the need of a nationwide antifungal stewardship program.
We thank Parthena Kyriklidou (Nephrology Department), Maria Kasapi (Otorhinolaryngology Department), Konstantinos Rossios (Cardiology Department), Sotirios Karatzoglou (Neurosurgery Department), and Thomas Rallis (Cardiothoracic Surgery Department) of the Papageorgiou University Affiliated Hospital.
This study was supported by internal funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of each participating hospital’s Ethics Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 3.Papadimitriou-Olivgeris M, Spiliopoulou A, Kolonitsiou F, Bartzavali C, Lambropoulou A, Xaplanteri P et al (2019) Increasing incidence of candidaemia and shifting epidemiology in favor of Candida non-albicans in a 9-year period (2009-2017) in a university Greek hospital. Infection 47:209–216CrossRefGoogle Scholar
- 5.De Pauw B, Walsh TJ, Donnelly JP, Garbino J, Kullberg BJ, Lortholary O et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821CrossRefGoogle Scholar
- 6.Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18:53–67CrossRefGoogle Scholar
- 9.Sipsas NV, Pagoni MN, Kofteridis DP, Meletiadis J, Vrioni G, Papaioannou M et al (2018) Management of invasive fungal infections in adult patients with hematological malignancies in Greece during the financial crisis: challenges and recommendations. J Fungi (Basel) 4.Google Scholar
- 10.Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P et al (2018) European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73:3221–3230PubMedGoogle Scholar
- 11.Papadimitriou-Olivgeris M, Spiliopoulou A, Fligou F, Spiliopoulou I, Tanaseskou L, Karpetas G et al (2017) Risk factors and predictors of mortality of candidemia among critically ill patients: role of antifungal prophylaxis in its development and in selection of non-albicans species. Infection 45:651–657CrossRefGoogle Scholar